What is Perosphere?
Perosphere operates at the intersection of pharmaceutical engineering and clinical medicine, focusing on the optimization of existing drug delivery mechanisms to enhance safety, efficacy, and patient outcomes. The company's core competency lies in identifying market gaps where novel delivery technology can repurpose established therapeutics or facilitate the development of new chemical entities. Its lead candidate, PER977, serves as a pivotal anticoagulant reversal agent targeting direct factor Xa- and IIa-inhibitors, addressing a significant unmet need in emergency medicine. Through its specialized approach, Perosphere effectively mitigates the risks associated with traditional drug development by focusing on high-value, rescue-oriented therapeutic applications that offer clear clinical utility and commercial scalability.
How much funding has Perosphere raised?
Perosphere has raised a total of $8.9M across 4 funding rounds:
Series A
$1M
Debt
$1.5M
Series B
$6.2M
Debt
$150K
Series A (2011): $1M, investors not publicly disclosed
Debt (2014): $1.5M led by Connecticut Innovations
Series B (2015): $6.2M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Key Investors in Perosphere
Connecticut Innovations
Connecticut Innovations is the state's strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies in the state scale, with dedicated funds for sectors like AI/quantum, climate tech, and biosciences.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Perosphere?
With the recent capital injection, Perosphere is poised to accelerate its clinical trial milestones and refine its regulatory strategy for its lead anticoagulant reversal candidate. The company's trajectory suggests a shift toward commercial readiness, requiring robust investment in manufacturing partnerships and clinical validation. As the firm continues to navigate the complex regulatory environment for specialty therapeutics, the focus will likely remain on securing additional strategic partnerships to facilitate the global distribution of its rescue drug portfolio. Investors are closely monitoring the firm's ability to translate its technical expertise into tangible market share within the high-stakes field of emergency anticoagulation management.
See full Perosphere company page
